David Liu: Gene Editing to Treat Rare Disease
Can rewriting DNA change the future for families living with rare genetic disease? Dr. David Liu joins Ron Kleiman to discuss base editing, prime editing, patients already benefiting from these technologies, and the work needed to reach more families. Recorded in Boston the day after Prime Medicine's October 5, 2026 announcement that the first patient had been dosed in its Phase 1/2 trial of PM577a, an investigational in vivo prime-editing treatment for Wilson disease. David's laboratory pioneered base editing and prime editing. He is a Harvard professor, director of the Merkin Institute for…